Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05356884
Other study ID # 2000031325
Secondary ID 1R01DK128277-01A
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 7, 2022
Est. completion date August 31, 2024

Study information

Verified date February 2024
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this project is to test the feasibility, acceptability, and preliminary efficacy of an adolescent-mediated intervention designed to improve the glycemic control and self-care practices of a parent/grandparent. The preliminary impact of the intervention on adult glycemic control (HbA1c) and self-care behaviors, as well as adolescent risk factors, will be explored with the goal of informing future programs that can be scaled to reduce diabetes burden and eliminate health disparities among at risk, ethnic minority groups.


Description:

The number of individuals diagnosed with Type 2 Diabetes in the United States (US) has more than doubled since 2000 to over 30 million, with an additional 84.1 million living with prediabetes. One minority group at particular risk is Pacific Islanders (PIs), who are at disproportionate risk and face many barriers (structural and cultural) to engaging in prevention or self-care. To address the critical need for diabetes prevention and treatment programs that target PIs, and building on the family-centered culture, the objective of this project is to pilot test and evaluate a randomized controlled trial of an adolescent-mediated intervention designed to improve the glycemic control and self-care practices of a paired, adult family member with diagnosed diabetes. Dyads (n=160 dyads; an adolescent without diabetes and a parent/grandparent diagnosed with diabetes who share a household) will be randomized. Adolescents will receive either a six-month diabetes intervention or a leadership and life skills-focused control curriculum in groups (n=10 participants in each group). Aside from planned research assessments there will be no contact with the adults in the dyad, who will proceed with their usual diabetes care. To test the hypothesis that adolescents receiving the intervention will be effective conduits of diabetes knowledge and will support their paired adult in the adoption of self-care strategies, the primary efficacy outcomes will be adult glycemic control and cardiovascular risk factors (BMI, blood pressure, waist circumference). Secondarily, since exposure to the intervention may encourage positive behavior change in the adolescent themselves similar outcomes will be measured in the adolescents. Outcomes will be measured at baseline, at the end of the active intervention phase (six months post-randomization) and at 12-months post-randomization, to examine maintenance of intervention effects in the absence of contact. To determine potential for long-term sustainability and scale up, program acceptability, feasibility, fidelity, reach, and cost will be examined. Successful completion of the study aims and proof of efficacy would produce an innovative, scalable program with high potential for replication in other similar, low-resource, family-centered, ethnic minority groups across the US who are the ideal beneficiaries of innovations to reduce chronic disease risk and eliminate health disparities.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 340
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years and older
Eligibility Inclusion Criteria: Adolescent - 14-17 years of age - Samoan ethnicity - Shares a household with a parent, legal guardian, or grandparent with type II diabetes - Willing and able to consent to participation - Able to participate in group sessions after school or on Saturday mornings Adult - Samoan ethnicity - Diagnosed with type II diabetes at least 12 months prior to study enrollment - HbA1c >= 6.5% - Prescribed medication (tablets or insulin) to control their diabetes - Willing and able to consent to participation - Willing and able to consent to adolescent's participation Exclusion Criteria: Adolescent - Planning to become pregnant during the study period (any adolescent who becomes pregnant will be excluded from analysis) - Planning to leave American Samoa in the next 18 months - Participants will be excluded if they report any of the following: - Uncontrolled hypertension (systolic >180 mmHg or diastolic >105 mmHg) - Heart attack, stroke, or transient ischemic attack in the past year - Treatment for cancer - Chest pain or shortness of breath with minimal activity - Chronic lung disease, or asthma requiring home oxygen therapy - Contraindications to moderate physical activity - Inability to read/speak Samoan and/or English. - Overt diabetes (HbA1c =6.5%) based on point-of-care testing during the screening process Adult - Planning to become pregnant during the study period (any adult who becomes pregnant will be excluded from analysis) - Planning to leave American Samoa in the next 18 months - Participants will be excluded if they report any of the following: - Uncontrolled hypertension (systolic >180 mmHg or diastolic >105 mmHg) - Heart attack, stroke, or transient ischemic attack in the past year - Treatment for cancer - Chest pain or shortness of breath with minimal activity - Chronic lung disease, or asthma requiring home oxygen therapy - Contraindications to moderate physical activity - Inability to read/speak Samoan and/or English.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Diabetes Intervention
A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
Leadership & Life Skills
A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)

Locations

Country Name City State
American Samoa OLaGA Research Center Pago Pago

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

American Samoa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Adult Glycemic Control (HbA1c) 0-6 months Glycated hemoglobin (marker of long term glycemic control) 0 - 6 months
Primary Change in Adult Glycemic Control (HbA1c) 0-12 months Glycated hemoglobin (marker of long term glycemic control) 0 - 12 months
Primary Change in Adult Glycemic Control (HbA1c) 6-12 months Glycated hemoglobin (marker of long term glycemic control) 6 - 12 months
Primary Change in Adult Body Mass Index (BMI) 0-6 months Body mass index (measure of weight control) 0 - 6 months
Primary Change in Adult Body Mass Index (BMI) 0-12 months Body mass index (measure of weight control) 0 - 12 months
Primary Change in Adult Body Mass Index (BMI) 6-12 months Body mass index (measure of weight control) 6 - 12 months
Primary Change in Adult Blood Pressure (BP) 0 - 6 months Blood Pressure (marker of hypertension risk) 0 - 6 months
Primary Change in Adult Blood Pressure (BP) 0 - 12 months Blood Pressure (marker of hypertension risk) 0 - 12 months
Primary Change in Adult Blood Pressure (BP) 6 - 12 months Blood Pressure (marker of hypertension risk) 6 - 12 months
Primary Change in Adult Waist Circumference (WC) 0 - 6 months Waist circumference (measure of weight control) 0 - 6 months
Primary Change in Adult Waist Circumference (WC) 0 - 12 months Waist circumference (measure of weight control) 0 - 12 months
Primary Change in Adult Waist Circumference (WC) 6 - 12 months Waist circumference (measure of weight control) 6 - 12 months
Secondary Change in Adolescent Glycemic Control (HbA1c) 0 - 6 months Glycated hemoglobin (marker of long term glycemic control) 0 - 6 months
Secondary Change in Adolescent Glycemic Control (HbA1c) 0 - 12 months Glycated hemoglobin (marker of long term glycemic control) 0 - 12 months
Secondary Change in Adolescent Glycemic Control (HbA1c) 6 - 12 months Glycated hemoglobin (marker of long term glycemic control) 6 - 12 months
Secondary Change in Adolescent Body Mass Index (BMI) 0 - 6 months Body mass index (measure of weight control) 0 - 6 months
Secondary Change in Adolescent Body Mass Index (BMI) 0 - 12 months Body mass index (measure of weight control) 0 - 12 months
Secondary Change in Adolescent Body Mass Index (BMI) 6 - 12 months Body mass index (measure of weight control) 6 - 12 months
Secondary Change in Adolescent Blood Pressure (BP) 0 - 6 months Blood Pressure (marker of hypertension risk) 0 - 6 months
Secondary Change in Adolescent Blood Pressure (BP) 0 - 12 months Blood Pressure (marker of hypertension risk) 0 - 12 months
Secondary Change in Adolescent Blood Pressure (BP) 6 - 12 months Blood Pressure (marker of hypertension risk) 6 - 12 months
Secondary Change in Adolescent Waist Circumference (WC) 0 - 6 months Waist circumference (measure of weight control) 0 - 6 months
Secondary Change in Adolescent Waist Circumference (WC) 0 - 12 months Waist circumference (measure of weight control) 0 - 12 months
Secondary Change in Adolescent Waist Circumference (WC) 6 - 12 months Waist circumference (measure of weight control) 6 - 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2